Preclinical Development Combinations of BRAF , MEK , and PI 3 K / mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK 2118436 Dabrafenib , Mediated by NRAS or MEK Mutations
2012
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI